Cannabidiol Plus Vitamin D in Hepatocellular Carcinoma

Key Findings

• In Hep3B and Huh7 hepatocellular carcinoma (HCC) cells, cannabidiol (CBD) and vitamin D each reduced viability dose-dependently, and the combination was synergistic by Chou-Talalay combination index analysis in both lines [1].
• With CBD held at a fixed 50 µM, the vitamin D half-maximal inhibitory concentration (IC50) in Hep3B fell from 43.70 µM to 15.48 µM, a 2.8-fold reduction; in Huh7 it fell from 52.35 µM to 26.42 µM, a roughly 2-fold reduction [1].
• The combination raised the early-apoptotic fraction in both lines (29.38% in Hep3B, 34.18% in Huh7), yet in Huh7 several canonical pro-apoptotic transcripts were paradoxically downregulated [1].
• In Hep3B, the combination produced pronounced G0/G1 arrest (84.61%) alongside suppression of PCNA, Ki-67, and survivin, and upregulation of autophagy genes; Huh7 showed a different transcriptional signature across nearly every readout [1].
• The authors attribute the divergence largely to TP53 status: Hep3B is p53-null, Huh7 carries mutant p53. The findings are entirely in vitro, transcript-level for mechanism, and were not tested against a clinical comparator [1].

Why hepatocellular carcinoma keeps drawing combination approaches

Hepatocellular carcinoma remains one of the more intractable solid tumors. It is the dominant form of primary liver cancer, and most patients present at a stage where curative resection, ablation, or transplantation is no longer on the table. For those patients, systemic therapy carries the load, and it carries it poorly: sorafenib, the first targeted agent to extend overall survival in advanced disease, delivers a modest benefit that is routinely eroded by toxicity and acquired resistance [1]. That gap between need and effective options is the standing invitation behind most of the natural-product oncology literature, and it is the reason a combination of two widely available agents draws attention.

Both halves of this particular pairing arrive with their own preclinical track record. CBD has been reported across numerous tumor models to suppress proliferation, induce apoptosis, promote autophagy, and interfere with cell cycle progression, and a 2025 systematic review of CBD in liver cancer specifically catalogs apoptosis, autophagy regulation, and modulation of the PI3K/AKT/mTOR axis as recurring mechanisms, while noting that the human evidence remains thin [2]. Vitamin D, beyond its classical role in calcium handling, exerts antiproliferative and prodifferentiation effects through the vitamin D receptor, and vitamin D deficiency has been identified as a negative prognostic factor in HCC patients [3]. The rationale for combining them is that they engage overlapping but non-identical stress pathways, so a lower dose of each might do the work of a higher dose of either.

That rationale is not unreasonable, and it sits inside a much larger body of work on cannabinoid antitumor activity that Hytiva Research has examined in its companion analysis of the recent cannabinoid antitumor preclinical meta-analysis (Creangă-Murariu et al.). The pattern that analysis describes, robust and reproducible signal in cell and animal models paired with an almost complete absence of confirmatory human trials, is the frame this study should be read inside. The present paper does not break that pattern. It deepens one corner of it.

What the study tested, and how

The investigators, working at Yeditepe University, used two human HCC lines, Hep3B and Huh7, both from established repositories [1]. Viability was measured by MTS assay at 24, 48, and 72 hours across a dose range for each agent alone (vitamin D from 3.12 to 100 µM, CBD from 6.25 to 200 µM). For the combination arm, CBD was fixed at 50 µM, a concentration the authors selected as non-toxic on its own, while vitamin D was titrated. Synergy was not asserted from the viability curves alone; it was quantified with the Chou-Talalay combination index, the standard median-effect method that defines synergy as a combination index below 1 [1, 4]. Apoptosis was assessed by Annexin V/propidium iodide flow cytometry at 72 hours, cell cycle distribution by propidium iodide staining, and a broad panel of apoptosis, cell cycle, proliferation, autophagy, and DNA damage response genes by quantitative RT-PCR.

Two design choices shape how far the results can travel. First, the mechanistic layer is transcriptional. RT-PCR reports message, not protein or enzyme activity, and the authors are explicit that immunoblot confirmation was not performed. Second, there is no normal-hepatocyte control and no clinically used comparator such as sorafenib or lenvatinib in the reported analyses. Both points are flagged again in the discussion below, because they bound the conclusions more than the synergy statistic does.

The headline: a synergistic collapse in viability, centered on Hep3B

The viability data are the cleanest part of the paper. In Hep3B, vitamin D and CBD monotherapies each reduced viability in a dose-dependent fashion, with IC50 values of 43.70 µM and 62.85 µM respectively. Adding CBD at a fixed 50 µM pulled the vitamin D IC50 down to 15.48 µM, a 2.8-fold reduction, and combination index analysis confirmed synergy rather than simple additivity [1]. Huh7 told a parallel story with a smaller effect size: monotherapy IC50 values of 52.35 µM (vitamin D) and 51.44 µM (CBD), with the combination dropping the vitamin D IC50 to 26.42 µM, a roughly 2-fold reduction, again synergistic by combination index [1].

This is the result that justifies the study, and it is worth stating precisely. The synergy is a calculated interaction between two agents in immortalized cells over three days, not a demonstration of tumor regression. Within those terms it is a genuine and internally consistent finding, and Hep3B, the more responsive of the two lines, is the appropriate center of gravity for interpreting the mechanism. The interesting question is not whether viability dropped, but why the two lines arrived at similar endpoints through visibly different molecular routes.

Apoptosis: a phenotype the transcripts do not fully explain

By Annexin V staining, the combination increased the early-apoptotic population in both lines, reaching 29.38% in Hep3B and 34.18% in Huh7 [1]. Notably, CBD alone did not meaningfully raise apoptotic or necrotic populations in either line; the apoptotic signal in the combination arm tracked more closely with vitamin D. This is worth pausing on, because CBD monotherapy did reduce viability (IC50 62.85 µM in Hep3B, 51.44 µM in Huh7) without inducing measurable apoptosis. A compound that lowers viability without driving cells into apoptosis is acting through a cytostatic or otherwise non-apoptotic route, at least at these concentrations, which reframes CBD’s contribution here: it behaves less as a standalone cytotoxic agent than as a partner compound whose value emerges in combination. Reading CBD as sensitizing the cells to vitamin D-associated apoptosis is a reasonable interpretation of that pattern, though it is our framing rather than a claim the authors make.

The gene-expression layer is where the story turns. In Hep3B, the combination raised effector caspase-7 transcript and vitamin D alone raised caspase-8, a pattern broadly consistent with engagement of apoptotic signaling [1]. In Huh7, the same combination that increased the Annexin V apoptotic fraction simultaneously reduced the pro-apoptotic transcripts caspase-7, BAX, and BAK, against a broader backdrop of suppressed apoptosis-related genes [1]. A flow-cytometric apoptotic phenotype rising while the canonical pro-apoptotic messages fall is not a contradiction to be smoothed over; it is the most informative observation in the dataset. The authors interpret it as evidence that, in Huh7, cell death proceeds through p53-independent or transcription-independent routes, the kinds of post-translational, mitochondrial, or alternative cell-death mechanisms that RT-PCR cannot see. That reading turns on the cell line’s p53 status, which is the thread that ultimately ties the whole dataset together and which the consolidated section below takes up in full. For now the relevant point is narrower: the discordance is also a reminder that transcript panels can mislead when read as proxies for protein-level activity, and it is exactly the gap that immunoblotting would need to close.

Cell cycle and proliferation: G1 arrest and a counterintuitive CDK4 rise

In Hep3B, the combination drove cells into G0/G1, with 84.61% of the population arrested there, the signature of a cytostatic block at the G1/S boundary [1]. The proliferation markers moved in agreement: PCNA, survivin, and Ki-67 transcripts all fell, with survivin and Ki-67 dropping to roughly a fifth of control. So far, coherent.

The wrinkle is CDK4. Rather than falling, CDK4 transcript rose under every treatment condition in Hep3B, more than doubling with the combination, even as CDK1 fell and the cells visibly arrested [1]. The authors read this increase as a compensatory or stress-induced response rather than a functional push through G1/S, noting that transcriptional induction of cyclin-dependent kinases under sustained cell-cycle stress does not necessarily translate into progression. That reading is plausible and consistent with the overall cytostatic phenotype, but it is an inference, and it is the sort of claim that protein and activity-level data would either support or dismantle. Huh7 was tidier on this axis: CDK1, CDK2, CDK4, and CDK6 were broadly downregulated, and proliferation markers fell across treatment groups [1].

Autophagy and DNA damage response: the two cell lines split

The autophagy and DNA-damage readouts are where Hep3B and Huh7 part company most plainly. In Hep3B, the combination upregulated the autophagy genes ATG5, BECLIN-1, and LC3B, pointing toward activation of autophagic signaling as a possible contributor to growth suppression [1]. Whether that transcriptional induction translates into completed autophagic flux is not something this dataset can establish, since flux requires turnover assays the study did not perform. In Huh7, the same three genes were downregulated across every treatment condition, suggesting suppressed rather than induced autophagy and a different adaptive posture entirely [1].

The DNA damage response panel followed the same fault line. In Hep3B, the combination produced an unbalanced profile: ATM, ATR, and BRCA2 fell while BRCA1 rose modestly [1]. The authors read this not as competent repair but as dysregulated or incomplete repair signaling, the kind of state that can leave a cell sensitized to growth arrest or death. In Huh7, the entire DNA damage response panel was downregulated, which the authors describe as a more global suppression of repair capacity. Two cell lines, one drug combination, opposite transcriptional directions on autophagy and DNA repair. That heterogeneity is the actual subject of the paper.

The p53 throughline that organizes the whole dataset

What keeps these scattered readouts from looking like noise is TP53 status, and the authors are right to make it the spine of their discussion. Hep3B carries a TP53 deletion and expresses no functional p53; Huh7 expresses a mutant p53 with partial residual function [1]. Once that is on the table, several of the apparent oddities line up. In Hep3B, with no p53 to coordinate the canonical apoptotic transcriptional program, the cell defaults to a cytostatic G1 arrest with autophagy induction and disordered DNA-damage signaling, a phenotype the authors suggest could even represent a senescence-like state rather than outright apoptosis. They are careful to flag that senescence markers were not directly measured, so this remains a hypothesis rather than a finding, and it should be cited as such. In Huh7, partial p53 function and a different mutational background yield a measurable apoptotic phenotype that nonetheless runs without, or even against, the canonical pro-apoptotic transcripts.

The practical message for anyone reading this as a translational lead is that the combination’s effect is not one mechanism but a family of context-dependent responses gated by the genetic background of the cell. That is a more honest and more useful conclusion than a single tidy pathway would have been, and it converges with the broader theme in Hytiva Research’s coverage of cannabinoid oncology, including Cancer Care Evolution: Future Palliative and Anti-Tumor Cannabis Studies, that cannabinoid antitumor activity in the laboratory is real, mechanistically plural, and still a long way from a defined clinical protocol.

What “vitamin D” actually means here, and why the concentration matters

One variable deserves more scrutiny than the paper gives it, and flagging it is less a criticism than a map of where the next experiments should go. The mechanistic rationale in the introduction rests on calcitriol, the active 1α,25-dihydroxyvitamin D3 hormone that binds the vitamin D receptor and regulates the relevant cell-cycle and apoptosis genes [1, 3]. The methods, as reported, refer simply to “vitamin D” across the dosing range without clearly resolving which species was applied in the assays. For a study whose entire premise is vitamin D receptor-mediated signaling, the identity of the vitamin D molecule used is not a detail; it determines how the mechanism should be modeled.

The concentrations compound the question. The active vitamin D IC50 values here sit between roughly 15 and 52 µM. Physiologically, circulating 25-hydroxyvitamin D is measured in the nanomolar range and active calcitriol in the picomolar range, so the effective concentrations in these assays exceed achievable serum vitamin D levels by several orders of magnitude. The same applies to the fixed 50 µM CBD. These are pharmacological exposures, not nutritional ones. That does not invalidate the synergy; it relocates it. It tells future investigators that any translational path would need to specify and justify the vitamin D species, define a concentration range tied to achievable tissue exposure, and probably contend with delivery, since systemic dosing to micromolar intratumoral vitamin D is not a realistic supplement scenario. Framed constructively, the concentration gap is a research-design prompt: it points toward analog selection, local or targeted delivery, and in vivo pharmacokinetics as the questions worth funding next.

This is also the natural place to be plain about the consumer narrative. Within hours of publication this study was already circulating in cannabis-focused media (example coverage). The finding that two over-the-counter compounds are synergistic against cultured liver cancer cells is precisely the kind of result that gets compressed into a “CBD and vitamin D treat liver cancer” claim. Nothing in the data supports that compression. The work is in vitro, uses concentrations unreachable through supplementation, and the authors themselves call for in vivo and clinical validation before any therapeutic claim is entertained. Reporting the science accurately means stating the synergy and stating its boundaries in the same breath.

Limits, and what would move this toward the clinic

The authors enumerate their own constraints candidly, and those constraints are the appropriate final word. The findings are restricted to in vitro HCC models and were not validated in normal hepatocytes or in any in vivo system, so selectivity for malignant over healthy liver tissue is unknown [1]. The mechanistic conclusions rest on transcriptional data without protein-level confirmation, which matters acutely here given the Huh7 apoptosis-versus-transcript discordance. And no clinically approved systemic therapy was run as a comparator, so the combination’s effect cannot be benchmarked against the current standard of care.

What would advance this signal is straightforward to specify, even if it is laborious to execute: immunoblot or activity-level confirmation of the implicated apoptotic, autophagic, and DNA-damage pathways; direct measurement of senescence markers to test the Hep3B senescence hypothesis; inclusion of non-malignant hepatocytes to establish a therapeutic window; head-to-head comparison with sorafenib or lenvatinib; and, eventually, in vivo work with a clearly defined vitamin D species and a defensible exposure strategy. Until then, the accurate summary is the modest one the data earn. In two HCC cell lines, combined CBD and vitamin D act synergistically to reduce viability and engage multiple stress pathways in a manner gated by TP53 status. That is a legitimate preclinical lead and a reasonable basis for the next experiments. It is not, and the study does not claim to be, evidence of clinical benefit.